Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Nov 10, 2014 2:10pm

263 Views

Post# 23114189

RE:RE:Dart Neuroscience: A lot Going On in San Diego

Hi GV:

Thanks for your question: No, I don't think that's his sole focus. He seems to have a keen interest in drugs that can enhance memory function across the board - not just related to Alzheimer's or dementia or related memory issues. Some of the focus seems to be on enhancing memory formation.

Looks like they are growing to 250 employees and have a new HQ location in San Diego County. You can see the new HQ here on their home page: https://www.dartneuroscience.com/Company.php

That's a lot of headcount! Seems like he is making quite an investment in drug development. Not just with RVX and Zenith.

Bullboard Posts

MDA Space stock blasts off on Q3 financial results